For the twelve months ended Jun 30, 2026, Verrica Pharmaceuticals Inc. reported $30.32M of revenue and -$31.18M of net income.
VRCA revenue was $5.86M in fiscal Q2 2026 (ended Jun 30, 2026), down 53.8% from a year earlier and up 16.7% from the prior quarter. For the full fiscal 2025 it was $35.58M, up 370.2% from fiscal 2024. It rose in 2 of the last 4 fiscal years. Fiscal 2025 is the highest of the 5 fiscal years on file.
VRCA net income was -$13.15M in fiscal Q2 2026 (ended Jun 30, 2026), compared with $204.0K a year earlier. For the full fiscal 2025 it was -$17.89M, compared with -$76.58M in fiscal 2024.
VRCA diluted EPS was -$0.62 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$1.68.
VRCA free cash flow was -$4.59M in fiscal Q4 2025 (ended Dec 31, 2025), compared with -$16.06M a year earlier. For the full fiscal 2025 it was -$17.63M, compared with -$60.95M in fiscal 2024.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35.58M | $7.57M | $5.12M | $9.03M | $12.00M | - | - | - | - |
| Cost of revenue | - | $2.60M | $500.0K | - | - | - | - | - | - |
| Gross profit | - | $4.97M | $4.62M | - | - | - | - | - | - |
| Research and development | $8.86M | $11.84M | $20.30M | $12.20M | $15.93M | $15.67M | $15.44M | $12.83M | $3.73M |
| Selling, general and admin | $35.22M | $58.82M | $47.30M | $17.41M | $26.98M | $24.51M | $14.64M | $9.05M | $727.0K |
| Operating income | -$12.19M | -$65.92M | -$65.76M | -$21.30M | -$30.91M | -$40.18M | -$30.08M | -$21.88M | -$4.46M |
| Interest expense | $7.74M | $9.41M | $3.96M | $2.17M | $4.29M | $3.03M | - | - | - |
| Income tax | $0 | $0 | $0 | $0 | - | - | - | - | - |
| Net income | -$17.89M | -$76.58M | -$67.00M | -$24.49M | -$35.08M | -$42.69M | -$28.21M | -$20.65M | -$4.46M |
| EPS, basic | -$1.68 | -$14.78 | -$14.80 | -$7.20 | -$13.00 | -$17.10 | -$11.30 | -$14.10 | -$15.60 |
| EPS, diluted | -$1.68 | -$14.78 | -$14.80 | -$7.20 | -$13.00 | -$17.10 | -$11.30 | -$14.10 | -$15.60 |
| Diluted shares | 10.7M | 5.2M | 4.5M | 3.4M | 2.7M | 2.5M | 2.5M | 1.5M | 285,026.9 |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $30.15M | $46.33M | $69.55M | $34.27M | $15.75M | $10.69M | $9.24M | $10.27M | $8.66M |
| Receivables | $5.26M | $48.0K | $4.25M | $0 | - | - | - | - | - |
| Inventory | $2.24M | $2.46M | $1.02M | $0 | - | - | - | - | - |
| Current assets | $42.54M | $51.18M | $77.53M | $39.12M | $74.33M | $67.65M | $64.98M | $91.15M | $9.08M |
| Total assets | $47.13M | $54.13M | $81.60M | $44.72M | $80.13M | $74.15M | $68.42M | $91.91M | $9.08M |
| Current liabilities | $16.44M | $29.01M | $17.02M | $3.46M | $46.05M | $39.48M | $3.35M | $2.48M | $616.0K |
| Short-term debt | $0 | $12.94M | $0 | $0 | $41.69M | $35.31M | - | - | - |
| Total debt | $0 | $30.98M | $42.87M | $0 | - | - | - | - | - |
| Total liabilities | $22.39M | $63.99M | $61.83M | $4.69M | $47.52M | $41.17M | $3.41M | $2.48M | $616.0K |
| Shareholders' equity | $24.74M | -$9.86M | $19.76M | $40.03M | $32.60M | $32.99M | $65.02M | $89.43M | -$7.04M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$17.63M | -$60.93M | -$38.58M | -$18.65M | -$27.58M | -$30.21M | -$27.41M | -$17.87M | -$4.58M |
| Capital expenditures | $0 | $27.0K | $362.0K | $302.0K | $883.0K | $1.47M | $682.0K | $774.0K | - |
| Free cash flow | -$17.63M | -$60.95M | -$38.94M | -$18.95M | -$28.46M | -$31.68M | -$28.09M | -$18.65M | - |
| Investing cash flow | $0 | -$19.0K | -$362.0K | $54.04M | -$998.0K | -$3.58M | $25.95M | -$79.89M | - |
| Financing cash flow | $1.45M | $37.73M | $74.21M | -$16.87M | $33.65M | $35.23M | $423.0K | $99.38M | $12.72M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 370.2% | 47.7% | -43.3% | -24.7% | - | - | - | - | - |
| Gross margin | - | 65.6% | 90.2% | - | - | - | - | - | - |
| Operating margin | -34.2% | -871.3% | -1283.4% | -235.8% | -257.6% | - | - | - | - |
| Net margin | -50.3% | -1012.1% | -1307.5% | -271.1% | -292.3% | - | - | - | - |
| Free cash flow margin | -49.5% | -805.6% | -759.9% | -209.8% | -237.2% | - | - | - | - |
| Return on equity | -72.3% | - | -339.0% | -61.2% | -107.6% | -129.4% | -43.4% | -23.1% | - |
| Return on assets | -37.9% | -141.5% | -82.1% | -54.8% | -43.8% | -57.6% | -41.2% | -22.5% | -49.1% |
| Current ratio | 2.59 | 1.76 | 4.55 | 11.31 | 1.61 | 1.71 | 19.39 | 36.80 | 14.75 |
| Debt to equity | 0.00 | - | 2.17 | 0.00 | - | - | - | - | - |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.86M | $5.02M | $5.09M | $14.34M | $12.70M | $3.44M | $344.0K | -$1.78M | $5.18M | $3.83M | $1.99M | $2.92M |
| Cost of revenue | - | - | - | - | - | $700.0K | $800.0K | $400.0K | $700.0K | $700.0K | $200.0K | $300.0K |
| Gross profit | - | - | - | - | - | $2.74M | -$456.0K | -$2.18M | $4.48M | $3.13M | $1.79M | $2.62M |
| Research and development | $6.03M | $3.86M | $2.52M | $2.21M | $1.85M | $2.28M | $1.17M | $2.40M | $3.32M | $4.95M | $5.32M | $6.51M |
| Selling, general and admin | $10.35M | $9.99M | $8.12M | $9.40M | $8.85M | $8.85M | $9.88M | $16.08M | $16.52M | $16.34M | $17.00M | $20.05M |
| Operating income | -$13.10M | -$9.71M | -$7.19M | $1.63M | $1.51M | -$8.13M | -$11.41M | -$20.70M | -$15.21M | -$18.60M | -$23.14M | -$23.92M |
| Interest expense | $164.0K | $160.0K | $1.31M | $2.09M | $2.13M | $2.20M | $2.35M | $2.38M | $2.37M | $2.32M | $2.31M | $1.66M |
| Net income | -$13.15M | -$9.68M | -$8.07M | -$274.0K | $204.0K | -$9.74M | -$16.20M | -$22.86M | -$17.19M | -$20.33M | -$24.61M | -$24.80M |
| EPS, basic | -$0.62 | -$0.45 | -$0.64 | -$0.03 | $0.02 | -$1.03 | -$1.80 | -$4.88 | -$3.70 | -$4.40 | -$5.50 | -$5.40 |
| EPS, diluted | -$0.62 | -$0.45 | -$0.64 | -$0.03 | $0.02 | -$1.03 | -$1.80 | -$4.88 | -$3.70 | -$4.40 | -$5.50 | -$5.40 |
| Diluted shares | 21.3M | 21.3M | - | 9.5M | 9.5M | 9.5M | - | 4.7M | 4.7M | 4.6M | - | 4.6M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $11.20M | $20.60M | $30.15M | $21.10M | $15.40M | $29.59M | $46.33M | $22.96M | $31.93M | $48.94M | $69.55M | $84.31M |
| Receivables | $10.94M | $7.72M | $5.26M | $7.05M | $9.19M | $5.61M | $48.0K | $0 | $10.03M | $7.00M | $4.25M | $3.95M |
| Inventory | $2.71M | $1.97M | $2.24M | $2.30M | $2.52M | $2.46M | $2.46M | $2.58M | $2.70M | $2.50M | $1.02M | $279.0K |
| Current assets | $32.64M | $34.13M | $42.54M | $36.27M | $36.78M | $39.47M | $51.18M | $28.19M | $47.32M | $61.38M | $77.53M | $91.72M |
| Total assets | $36.02M | $38.79M | $47.13M | $40.90M | $39.11M | $42.18M | $54.13M | $32.93M | $52.01M | $66.31M | $81.60M | $97.15M |
| Current liabilities | $22.44M | $16.22M | $16.44M | $28.91M | $29.22M | $29.40M | $29.01M | $21.03M | $20.05M | $19.36M | $17.02M | $11.37M |
| Short-term debt | - | - | $0 | $12.46M | $12.67M | $12.82M | $12.94M | - | - | - | $0 | - |
| Total debt | - | - | $0 | $21.62M | $24.58M | $27.81M | $30.98M | $43.30M | $42.75M | $42.85M | $42.87M | $42.40M |
| Total liabilities | $31.71M | $22.73M | $22.39M | $57.94M | $56.59M | $60.75M | $63.99M | $66.98M | $65.31M | $64.80M | $61.83M | $54.84M |
| Shareholders' equity | $4.31M | $16.05M | $24.74M | -$17.04M | -$17.48M | -$18.58M | -$9.86M | -$34.05M | -$13.30M | $1.51M | $19.76M | $42.30M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.28M | -$9.16M | -$4.59M | $9.69M | -$10.04M | -$12.68M | -$16.06M | -$8.56M | -$16.36M | -$19.95M | -$14.51M | -$14.81M |
| Capital expenditures | - | - | $0 | $0 | - | - | $0 | $16.0K | $11.0K | $0 | $227.0K | $65.0K |
| Free cash flow | - | - | -$4.59M | $9.69M | - | - | -$16.06M | -$8.57M | -$16.37M | -$19.95M | -$14.73M | -$14.88M |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 | $0 | $8.0K | -$16.0K | -$11.0K | $0 | -$227.0K | -$65.0K |
| Financing cash flow | -$126.0K | -$120.0K | $13.64M | -$3.98M | -$4.16M | -$4.06M | $39.43M | -$397.0K | -$640.0K | -$661.0K | -$27.0K | $44.04M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -53.8% | 46.1% | 1380.2% | - | 145.4% | -10.1% | -82.7% | -161.1% | 2744.5% | 10240.5% | 2823.5% | -64.9% |
| Gross margin | - | - | - | - | - | 79.6% | -132.6% | - | 86.5% | 81.7% | 89.9% | 89.7% |
| Operating margin | -223.4% | -193.4% | -141.2% | 11.3% | 11.9% | -236.4% | -3316.9% | - | -293.7% | -486.1% | -1163.8% | -819.9% |
| Net margin | -224.4% | -192.8% | -158.6% | -1.9% | 1.6% | -283.3% | -4709.9% | - | -332.0% | -531.4% | -1238.1% | -850.3% |
| Free cash flow margin | - | - | -90.2% | 67.5% | - | - | -4669.8% | - | -316.2% | -521.4% | -741.1% | -510.0% |
| Current ratio | 1.45 | 2.10 | 2.59 | 1.25 | 1.26 | 1.34 | 1.76 | 1.34 | 2.36 | 3.17 | 4.55 | 8.06 |
| Debt to equity | - | - | 0.00 | - | - | - | - | - | - | 28.41 | 2.17 | 1.00 |
Source: XBRL data Verrica Pharmaceuticals Inc. files with the SEC, latest filing dated Aug 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Aug 12, 2025.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| VRCA | $30.32M | +106.2% | -$31.18M | -102.8% | $63.9M |
| PTHS | $43.30M | - | -$86.39M | -199.5% | $31.6M |